Guardant Health, Inc.
Guardant Health, Inc. (GH) develops blood-based (liquid biopsy) tests and analytics for cancer detection, treatment selection and disease monitoring. Its products — including tumour profiling assays used for therapy decisions and tests aimed at early detection — leverage genomic sequencing and clinical data to address unmet needs in precision oncology. The company competes on technology, clinical validation and partnerships with biopharma and health systems, while seeking broader reimbursement and adoption. Guardant’s market cap is around $8.42 billion; investors should weigh potential growth from expanding test use against execution, regulatory, reimbursement and competitive risks. Financial performance has varied as the company invests in R&D and commercial expansion. This summary is educational only and not investment advice; suitability depends on an investor’s objectives, risk tolerance and timeframe, and past performance is not a reliable guide to future results.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Guardant Health's stock due to a slight expected price increase.
Financial Health
Guardant Health is performing well with solid revenue and cash flow, supported by high profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring GH
Diagnostic Takeover Targets
This carefully selected group of stocks features innovative diagnostic companies that could become acquisition targets following recent takeover interest in the sector. Professional analysts have identified these companies for their unique technologies and established market positions in a consolidating healthcare landscape.
Published: July 15, 2025
Explore BasketLiquid-Biopsy Diagnostics
These innovative companies are developing revolutionary blood tests that can detect cancer earlier and more accurately than ever before. Carefully selected by healthcare investment experts, this collection represents the forefront of non-invasive diagnostics poised to transform the multi-billion dollar oncology market.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Growth in Oncology Testing
Rising use of targeted therapies can increase demand for genomic tests, though adoption depends on guidelines and reimbursement which can take time.
Technology and Data
Combining sequencing with clinical datasets may create differentiation, yet technological competition and validation needs remain important considerations.
Market and Reimbursement
Expansion into new markets and payer coverage would support revenue, but regulatory and reimbursement outcomes introduce meaningful uncertainty.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
